Aaron L Berkowitz1, M Brandon Westover2, Matt T Bianchi2, Sherry H-Y Chou2. 1. From the Department of Neurology (A.L.B., S.H.C.), Brigham and Women's Hospital, Harvard Medical School; and Department of Neurology (M.B.W., M.T.B.), Massachusetts General Hospital, Harvard Medical School, Boston. aberkowitz3@partners.org. 2. From the Department of Neurology (A.L.B., S.H.C.), Brigham and Women's Hospital, Harvard Medical School; and Department of Neurology (M.B.W., M.T.B.), Massachusetts General Hospital, Harvard Medical School, Boston.
Abstract
OBJECTIVE: To analyze the potential impact of aspirin therapy for long-term secondary prevention after stroke of undetermined etiology in resource-limited settings without access to neuroimaging to distinguish ischemic stroke from intracerebral hemorrhage (ICH). METHODS: We conducted a decision analysis using a Markov state transition model. Sensitivity analyses were performed across the worldwide reported range of the proportion of strokes due to ICH and the 95% confidence intervals (CIs) of aspirin-associated relative risks in patients with ICH. RESULTS: For patients with stroke of undetermined etiology, long-term aspirin was the preferred treatment strategy across the worldwide reported range of the proportion of strokes due to ICH. At 34% of strokes due to ICH (the highest proportion reported in a large epidemiologic study), the benefit of aspirin remained beyond the upper bounds of the 95% CIs of aspirin-associated post-ICH relative risks most concerning to clinicians (ICH recurrence risk and mortality risk if ICH recurs on aspirin). Based on the estimated 11,590,204 strokes in low- and middle-income countries in 2010, our model predicts that aspirin therapy for secondary stroke prevention in all patients with stroke in these countries could lead to an estimated yearly decrease of 84,492 recurrent strokes and 4,056 stroke-related mortalities. CONCLUSIONS: The concern that the risks of aspirin in patients with stroke of unknown etiology could outweigh the benefits is not supported by our model, which predicts that aspirin for secondary prevention in patients with stroke of undetermined etiology in resource-limited settings could lead to decreased stroke-related mortality and stroke recurrence.
OBJECTIVE: To analyze the potential impact of aspirin therapy for long-term secondary prevention after stroke of undetermined etiology in resource-limited settings without access to neuroimaging to distinguish ischemic stroke from intracerebral hemorrhage (ICH). METHODS: We conducted a decision analysis using a Markov state transition model. Sensitivity analyses were performed across the worldwide reported range of the proportion of strokes due to ICH and the 95% confidence intervals (CIs) of aspirin-associated relative risks in patients with ICH. RESULTS: For patients with stroke of undetermined etiology, long-term aspirin was the preferred treatment strategy across the worldwide reported range of the proportion of strokes due to ICH. At 34% of strokes due to ICH (the highest proportion reported in a large epidemiologic study), the benefit of aspirin remained beyond the upper bounds of the 95% CIs of aspirin-associated post-ICH relative risks most concerning to clinicians (ICH recurrence risk and mortality risk if ICH recurs on aspirin). Based on the estimated 11,590,204 strokes in low- and middle-income countries in 2010, our model predicts that aspirin therapy for secondary stroke prevention in all patients with stroke in these countries could lead to an estimated yearly decrease of 84,492 recurrent strokes and 4,056 stroke-related mortalities. CONCLUSIONS: The concern that the risks of aspirin in patients with stroke of unknown etiology could outweigh the benefits is not supported by our model, which predicts that aspirin for secondary prevention in patients with stroke of undetermined etiology in resource-limited settings could lead to decreased stroke-related mortality and stroke recurrence.
Authors: Aaron L Berkowitz; Manoj K Mittal; Hannah C McLane; Gordon C Shen; Rajanandini Muralidharan; Jennifer L Lyons; Russell T Shinohara; Ashfaq Shuaib; Farrah J Mateen Journal: Int J Stroke Date: 2013-11-10 Impact factor: 5.266
Authors: Valery L Feigin; Carlene M M Lawes; Derrick A Bennett; Suzanne L Barker-Collo; Varsha Parag Journal: Lancet Neurol Date: 2009-02-21 Impact factor: 44.182
Authors: Craig S Anderson; Emma Heeley; Yining Huang; Jiguang Wang; Christian Stapf; Candice Delcourt; Richard Lindley; Thompson Robinson; Pablo Lavados; Bruce Neal; Jun Hata; Hisatomi Arima; Mark Parsons; Yuechun Li; Jinchao Wang; Stephane Heritier; Qiang Li; Mark Woodward; R John Simes; Stephen M Davis; John Chalmers Journal: N Engl J Med Date: 2013-05-29 Impact factor: 91.245
Authors: Jeyaraj Durai Pandian; Vasantha Padma; Pamidimukkala Vijaya; P N Sylaja; Jagaralpudi M K Murthy Journal: Int J Stroke Date: 2007-02 Impact factor: 5.266
Authors: Rita V Krishnamurthi; Valery L Feigin; Mohammad H Forouzanfar; George A Mensah; Myles Connor; Derrick A Bennett; Andrew E Moran; Ralph L Sacco; Laurie M Anderson; Thomas Truelsen; Martin O'Donnell; Narayanaswamy Venketasubramanian; Suzanne Barker-Collo; Carlene M M Lawes; Wenzhi Wang; Yukito Shinohara; Emma Witt; Majid Ezzati; Mohsen Naghavi; Christopher Murray Journal: Lancet Glob Health Date: 2013-10-24 Impact factor: 26.763
Authors: Valery L Feigin; Mohammad H Forouzanfar; Rita Krishnamurthi; George A Mensah; Myles Connor; Derrick A Bennett; Andrew E Moran; Ralph L Sacco; Laurie Anderson; Thomas Truelsen; Martin O'Donnell; Narayanaswamy Venketasubramanian; Suzanne Barker-Collo; Carlene M M Lawes; Wenzhi Wang; Yukito Shinohara; Emma Witt; Majid Ezzati; Mohsen Naghavi; Christopher Murray Journal: Lancet Date: 2014-01-18 Impact factor: 79.321
Authors: Adnan I Qureshi; Mohammad R Afzal; Ahmed A Malik; Mushtaq H Qureshi; Nauman Jahangir; M Fareed K Suri Journal: J Vasc Interv Neurol Date: 2015-10
Authors: Aaron Berkowitz; Nirali Vora; Morgan L Prust; Deanna Saylor; Stanley Zimba; Fred Stephen Sarfo; Gentle S Shrestha Journal: Stroke Date: 2022-01-20 Impact factor: 7.914
Authors: Hae-Won Koo; Minkyung Oh; Hyung Koo Kang; Yung Ki Park; Byung-Jou Lee; Seong Rok Han; Sang Won Yoon; Chan Young Choi; Moon-Jun Sohn; Chae Heuck Lee Journal: PLoS One Date: 2019-09-04 Impact factor: 3.240
Authors: Julie Lajoie; Kenzie Birse; Lucy Mwangi; Yufei Chen; Juliana Cheruiyot; Maureen Akolo; John Mungai; Genevieve Boily-Larouche; Laura Romas; Sarah Mutch; Makobu Kimani; Julius Oyugi; Emmanuel A Ho; Adam Burgener; Joshua Kimani; Keith R Fowke Journal: J Int AIDS Soc Date: 2018-07 Impact factor: 5.396